Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06408688
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-20
First Post:
2024-05-07
Brief Title:
Safety and Modulation of Adaptive Immunity by Iscador Qu Viscum Album Extract in Patients With Advanced Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Sponsor:
University Hospital Basel Switzerland
Organization:
University Hospital Basel Switzerland
Study Overview
Official Title:
Safety and Modulation of Adaptive Immunity by Iscador Qu Viscum Album Extract in Patients With Advanced Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors - a Randomized Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ISCA-CHECK
Brief Summary:
The main objective of this study is to test if adding the mistletoe extract Iscador Qu to regular cancer treatment with immune checkpoint inhibitors affects
The immune systems ability to fight cancer
Safety of the treatment
How well the treatment performs against cancer
How the patient feels during treatment
Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador Qu with patients treated with imune checkpoint inhibitors only
The immune systems ability to fight cancer
Safety of the treatment
How well the treatment performs against cancer
How the patient feels during treatment
Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador Qu with patients treated with imune checkpoint inhibitors only
Detailed Description:
The impact of mistletoe preparations - that are claimed to have immunostimulatory properties - on cancer treatment with immune checkpoint inhibitors remains unclear To address this knowledge gap the current study aims to investigate the modulation of adaptive immunity through the combination of Iscador a specific mistletoe preparation and immune checkpoint inhibitors Additionally researchers will evaluate the safety profile of this combination therapy in patients with locally advanced non-operable or metastatic cancers except for skin cancers By examining the modulation of adaptive immunity and safety of this treatment approach researchers aim to provide valuable insights for clinicians and patients in the context of advanced cancer care
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None